Santarus acquires, develops, and commercializes proprietary products for gastrointestinal diseases. Their current products include Uceris, approved for ulcerative colitis, and Zegerid, a combination pill for reducing stomach acid. They also have treatments for Type 2 diabetes and high cholesterol. Santarus' strategy is to develop and market products with new formulations or expanded indications based on clinically proven compounds.